Send to

Choose Destination
Nat Med. 1995 Jun;1(6):528-33.

A single-injection protein kinase A-directed antisense treatment to inhibit tumour growth.

Author information

Cellular Biochemistry Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-1750, USA.


Expression of the RI alpha subunit of cAMP-dependent protein kinase type I is enhanced in human cancer cell lines, in primary tumours, in cells after transformation and in cells upon stimulation of growth. We have investigated the effect of sequence-specific inhibition of RI alpha gene expression on in vivo tumour growth. We report that single injection RI alpha antisense treatment results in a reduction in RI alpha expression and inhibition of tumour growth. Tumour cells behaved like untransformed cells by making less protein kinase type I. The RI alpha antisense, which produces a biochemical imprint for growth control, requires infrequent dosing to halt neoplastic growth in vivo.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center